文献速递肝肾功能剂量调整

严重肾功能不全对balcinrenone药代动力学、安全性和耐受性的影响

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone.
PubMed 文献 · Br J Clin Pharmacol · 2025-02-17

这项1期试验比较了严重肾功能不全(eGFR<30 mL/min/1.73 m2)未透析患者与肾功能正常对照者单次口服150 mg balcinrenone后的药代动力学。严重肾功能不全组总表观清除率降低50%,AUC约高2倍,Cmax高1.4倍,药物安全且耐受良好。基于线性回归分析,eGFR 20相比60 mL/min/1.73 m2者AUC预计增高<50%,正在进行的MIRO-CKD和BalanceD-HF研究无需根据eGFR调整剂量。

要点

  • 严重肾功能不全者balcinrenone总表观清除率降低50%,AUC约高2倍。
  • 严重肾功能不全者Cmax高1.4倍,终末半衰期和血浆蛋白结合率相似。
  • 所有不良事件为轻至中度,未认为与balcinrenone相关。

核心结论

  • 严重肾功能不全患者balcinrenone暴露量约为匹配对照组的2倍。
  • 基于线性回归分析,eGFR 20相比60 mL/min/1.73 m2者AUC预计增高<50%。
  • 正在进行的MIRO-CKD和BalanceD-HF研究无需根据eGFR调整剂量。

研究设计与样本

  • 1期试验,比较严重肾功能不全(eGFR<30 mL/min/1.73 m2)未透析患者与eGFR≥90 mL/min/1.73 m2的匹配对照组。
  • 符合条件的参与者单次口服150 mg balcinrenone,采集血和尿样本进行分析。

主要发现

  • 严重肾功能不全组总表观balcinrenone清除率降低50%。
  • 严重肾功能不全组AUC约高2倍,Cmax高1.4倍,终末半衰期和血浆蛋白结合率两组相似。
  • balcinrenone在所有参与者中安全且耐受良好,不良事件均为轻至中度且未认为与药物相关。

关键数值与推荐

  • 严重肾功能不全定义为eGFR<30 mL/min/1.73 m2且未透析。
  • 对照组eGFR≥90 mL/min/1.73 m2。
  • 单次口服剂量为150 mg。

临床怎么用

  • 在严重肾功能不全患者中,balcinrenone暴露量约增加2倍。
  • 正在进行的MIRO-CKD和BalanceD-HF研究无需根据eGFR调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this phase 1 trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment vs. those with normal renal function. METHODS: Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2) not on dialysis were compared with group-matched control participants with eGFR ≥ 90 mL/min/1.73 m2. Eligible participants received a single oral dose of 150 mg balcinrenone, and blood and urine samples were collected for analysis. RESULTS: The total apparent balcinrenone clearance was 50% lower in the severe renal impairment group, resulting in an approximately two-fold higher area under the curve (AUC) and a 1.4-fold higher maximum observed plasma concentration in the severe renal impairment group compared with the control group. The terminal half-life and plasma protein binding were similar in both groups. Balcinrenone was safe and well tolerated in all participants. All reported adverse events were of mild-to-moderate severity and not considered related to balcinrenone. CONCLUSIONS: Balcinrenone exposure was approximately two-fold higher in participants with severe renal impairment compared with the group-matched control participants. Based on linear regression analysis of total apparent balcinrenone clearance vs. baseline eGFR, the AUC exposure is predicted to be <50% higher in patients with an eGFR of 20 mL/min/1.73 m2 compared with those with an eGFR of 60 mL/min/1.73 m2. In light of these findings, no dose adjustment based on eGFR is needed in two ongoing studies that target these patients (MIRO-CKD [NCT06350123] and BalanceD-HF [NCT06307652]).

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Bhattacharya CS, Ericsson H, Johansson S, et al. The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone. Br J Clin Pharmacol. 2025. PMID: 39962632. doi:10.1002/bcp.70017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。